REGENXBIO Inc. reported its financial results for the third quarter ended September 30, 2024, on November 6, 2024. The company's cash, cash equivalents, and marketable securities stood at $278.6 million as of September 30, 2024.
Total revenues for the three months ended September 30, 2024, were $24.2 million, a decrease from $28.9 million for the same period in 2023. This decline was primarily attributed to a decrease in Zolgensma royalty revenues.
The net loss for the third quarter of 2024 was $59.6 million, or $1.17 per basic and diluted share, an improvement compared to a net loss of $61.9 million, or $1.41 per share, in the third quarter of 2023. The company expects its cash position to fund operations into 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.